Cited by 584Psychedelics and Drug StudiesSubstance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, Teri S, Johansen, Pål-Ørjan·2012·Journal of Psychopharmacology

DOI 10.1177/0269881112439253

Open this paper in CoChat — free account

Abstract

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD on alcohol misuse (OR, 1.96; 95% CI, 1.36–2.84; p = 0.0003). Between-trial heterogeneity for the treatment effects was negligible (I 2 = 0%). Secondary outcomes, risk of bias and limitations are discussed. A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse.

Integrity signals

Registry

Crossref · 10.1177/0269881112439253

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Untitled work
(2008) · Cited by 3,790
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 762
Alcohol-use disorders
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 715
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455

Show all 39 references

Research works printed but not linked: 6

Ables MF, 1967, Highlights of the twelfth annual conference in cooperative studies in psychiatry
Ables MF, 1970, Group treatment of chronic alcoholism with LSD-25: study II. Newsletter for research in psychology, United States Veterans Administration, 12, 17
American Psychiatric Association (1952) Diagnostic and Statistical Manual for Mental Disorders. First Edition. Washington, DC: American Psychiatric Association, 39.
Kurland AA, 1971, Advances in neuropsychopharmacology: proceedings of the 7th congress of the collegium internationale neuro-psychopharmacologicum, 361
Rösner S, 2010, Cochrane Database Syst Rev, 9, CD004332
Rösner S, 2010, Cochrane Database Syst Rev, 12, CD001867

Sorted by citations

Items 401–500 of 584

Rewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process Theory
Vargas-Pérez, H., Minauro‐Sanmiguel, F., Ting‐A‐Kee, R. A., Grieder, T. E., Méndez‐Díaz, M., Prospero-Garcia, O. E., & van der Kooy, D. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137597 · Cited by 3
Established sensitization of ethanol-induced locomotor activity is not reversed by psilocybin or the 5-HT2A receptor agonist TCB-2 in male DBA/2J mice
Fletcher, P. J., Li, Z., Ji, X. D., & Lê, A. D. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173703 · Cited by 3
Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder
Aghaei, A. M., Weleff, J., Martins, B. S., Ing, K., Fontenele, R., Barnett, B. S., Anand, A., & Nia, A. B. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00574-y · Cited by 2
Survey of Massachusetts peer recovery coaches’ attitudes toward the use of psychedelics to treat substance use disorders
Szpak, V., Kim, A., Sager, Z. S., & Suzuki, J. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00517-y · Cited by 2
Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need
de Jonge, D., van der Meer, P. B., Kramers, C., & Schellekens, A. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01567-4 · Cited by 3
Psychedelic Use and Behavioral Addictions
Brasher, T. J., Rosen, D., & Spinella, M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2474244 · Cited by 2
The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?
Norman, T. R. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.1006105 · Cited by 2
Can Failure Carefully Observed Become a Springboard to Success?
Adrian, M. (2012) · Substance Use & Misuse · doi:10.3109/10826084.2012.706178 · Cited by 2
Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report
Johnson, S., & Black, Q. C. (2020) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-020-00398-7 · Cited by 4
Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature
Nigam, K. B., & Pandurangi, A. K. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-00871-x · Cited by 2
Integrating the ineffable: a social phenomenological analysis of the psychedelic experience
Neitzke‐Spruill, L. (2025) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/dyjg-0344 · Cited by 2
The psychedelic, DOI, increases dopamine release in nucleus accumbens to predictable rewards and reward cuesPreprint
Martin, D. A., Delgado, A., & Calu, D. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.29.587390 · Cited by 2
Hype or hope? The developing evidence base for psychedelic treatment of addiction disorders
Roberts, E. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.19 · Cited by 2
Stimulant Drugs: Introduction
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.006 · Cited by 1
Articulation de la thérapie d’acceptation et d’engagement à la psychothérapie assistée par psychédéliques en addictologie
Strika-Bruneau, L., Fauvel, B., Dupuis, D., & Benyamina, A. (2023) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2023.01.003 · Cited by 1
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction
Glenn, D. L., Choi, S. H., & Zimmerman, R. S. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251353251 · Cited by 1
The first applications of mescaline in psychiatry: The case of Madame Louise Françoise R. and its contemporary relevance
Hendrickx, M., Dampierre, A., & Drouin, E. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110707 · Cited by 1
A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder
Srivastava, A. B., & Gold, M. S. (2025) · Brain Sciences · doi:10.3390/brainsci15111190 · Cited by 3
Virtual reality and psychedelics: new perspectives and new possibilities in the treatment of alcohol use disorder
Matthews, S. C., Greco, A., Rastelli, C., & Nia, A. B. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1448043 · Cited by 1
Exploring practitioners’ perceptions of health behavior changes associated with psychedelic experiences
de Carvalho, L. L., Encantado, J., van Elk, M., Moller, A. C., Cornelius, T. M., Timmermann, C., Veiga, D., & Teixeira, P. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-25818-3 · Cited by 1
Psychedelics for the Treatment of Substance Use Disorders
Klaus, J., Schneider, F., Schaletzky, R., Sippel, D., & Batra, A. (2025) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000953 · Cited by 2
Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen
Wopfner, A., & Soravia, L. M. (2025) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000956 · Cited by 1
A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
Rich, R., Laird, K. T., Siddarth, P., Youssef, B., Schwartz, G. M., Ramos, A., Sergi, K., Linton, M., Schwartzberg, L., Kelly, D. F., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251387655 · Cited by 1
Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment
Lodetti, G., Réus, G. Z., & Rico, E. P. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.01.022 · Cited by 1
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials
McManus, K. R., & Ray, L. A. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2625341 · Cited by 2
Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution
Matsukubo, J., Friesen, E. L., MacDonald‐Spracklin, R., Iseman, R., Solmi, M., Fiedorowicz, J. G., Fischer, B., & Myran, D. T. (2026) · Canadian Journal of Public Health · doi:10.17269/s41997-026-01178-x · Cited by 1
Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland
Kelly, J. R., Sheridan, C., Iusan, P., Coakley, L., Burke, L., Brennan, C., MacDonald, A. A., Ivers, J., Trépel, D., Tormey, G., et al. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag028 · Cited by 1
Intention-Setting Among Recreational Psychedelic Users: Associated Acute Effects and Changes in Well-Being
Low, F., & Earleywine, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2673844 · Cited by 2
Integrating psychedelic-assisted psychotherapy into addiction care in the Czech Republic: Clinical evidence, safety, and regulatory developments
Postránecká, Z., Lucký, M., Mravčík, V., & Páleníček, T. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00514 · Cited by 1
Psychedelics and longevity: implications for lifespan, healthspan and functional aging
Haden, M., Woods, B., Woods, T., & Tupper, K. W. (2026) · Longevity · doi:10.1080/30653495.2026.2696224 · Cited by 1
Lysergic Acid Diethylamide and Mystical Experiences
Lyvers, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00078-9 · Cited by 1
PSILOCYBIN RESEARCH AT JOHNS HOPKINS: A 2014 REPORT
Jesse, R. L., & Griffi, R. R. (2014) · Cited by 1
Peyote’s Race Problem
Dawson, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-76720-8_2 · Cited by 1
The metabolism of indoleamines
Tricklebank, M. D., & Martins, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813323-1.00001-3 · Cited by 1
Drugs in therapy. LSD, MDMA, marijuana, psilocybin, designer drugs and its potential in modern medicine.
Tadeja, A. (2020) · Farmacja Polska · doi:10.32383/farmpol/127922 · Cited by 1
Psychedelika
von Heyden, M., & Jungaberle, H. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_43 · Cited by 1
Pharmacological Action of LSD
Herian, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_131-2 · Cited by 2
Reconsidering Context in Psychedelic Research: Rituals as Ancient Libraries of Knowledge
Lutz, H. (2023) · Journal of Scientific Exploration · doi:10.31275/20222441 · Cited by 1
Lysergic acid diethylamide: In search of the wonder drug
Avram, M., Müller, F., & Borgwardt, S. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192863607.003.0005 · Cited by 1
Uso de psicodélicos para tratamento de transtornos psiquiátricos: uma revisão integrativa
de Souza, P. H. M., & Souza, G. P. (2023) · Bionorte · doi:10.47822/bn.v12isuppl.2.528 · Cited by 1
Psychedelic-Assisted Therapy and Meditative Experience as Factors of Personal Change
Omelchenko, N., & Kurapov, A. (2023) · Bulletin of Taras Shevchenko National University of Kyiv Psychology · doi:10.17721/bpsy.2023.1(17).8 · Cited by 1
Medical Use of Cannabinoids and Psychedelic Compounds
Inserra, A., Gregorio, D. D., & Gobbi, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_141-1 · Cited by 1
Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Ghosh, P., & Sur, D. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822258502231120074036 · Cited by 1
Geschichte der Anwendung von Psychedelika
Herwig, U. (2024) · Nervenheilkunde · doi:10.1055/a-2306-6120 · Cited by 1
Introduction: philosophy and psychedelic psychiatry
Letheby, C., & Gerrans, P. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0001 · Cited by 1
Evaluating the Therapeutic Utility of Hallucinogens for Substance Use Disorders
Dakwar, E. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_33 · Cited by 1
LAS PLANTAS Y LOS HONGOS ALUCINÓGENOS: REFLEXIONES PRELIMINARES SOBRE SU ROL EN LA EVOLUCIÓN HUMANA HALLUCINOGENIC PLANTS AND MUSHROOMS: PRELIMINARY REFLECTIONS ON THEIR ROLE IN HUMAN EVOLUTION
Arce, J. M. R. (2012) · Dialnet (Universidad de la Rioja) · Cited by 1
Addictions
Vogel, M., Strasser, H., Thorens, G., ZULLINO, D. F., Humair, J., Simon, O., Broers, B., Haettel, C., Dévaud, C., Gothuey, I., et al. (2020) · JMIG · doi:10.53738/revmed.2020.16.676-77.0008 · Cited by 1
Can psychedelic-assisted psychotherapy play a role in enhancing motivation to change in addiction treatment settings?
Kang, M., Mackay, L., Christie, D., Callon, C., & Argento, E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00190 · Cited by 1
Psychedelic therapy for body dysmorphic disorder
Johnson, S., & Letheby, C. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00200 · Cited by 1
Pharmacological Action of LSD
Herian, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_131 · Cited by 1
The Buddhist Noble Truths: Are They True?
Bronkhorst, J. (2023) · Religions · doi:10.3390/rel14010082 · Cited by 3
Myths and facts about drug policy formulation
Medeiros, D., & Tófoli, L. F. (2023) · Boletim de Análise Político-Institucional · doi:10.38116/bapi33art7 · Cited by 1
How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence by Michael Pollan
Harrington, C. (2022) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2022.29 · Cited by 1
Ibogaine as a Treatment For Alcohol Use Disorder: a Preclinical Investigation
Falkenhaug, S. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.24225145 · Cited by 1
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy TrialsPreprint
Haft, S. L., Downey, A. E., Raymond‐Flesch, M., Fernandes‐Osterhold, G., Bradley, E., O’Donovan, A., & Woolley, J. D. (2024) · doi:10.31219/osf.io/ewyn2 · Cited by 1
MDMA, Internal Family Systems therapy, and the Minnesota model in the resolution of C-PTSD-induced alcohol and diazepam addiction—A retrospective case studyPreprint
Turkia, M. (2023) · doi:10.31234/osf.io/fpb83 · Cited by 1
How Current Drug Laws Impede Research and Clinical Treatments
Nutt, D. J. (2013) · Wiley eBooks · doi:10.1002/9781118306604.ch12
Dependência, recuperação e o tratamento através da ayahuasca: definições e indefinições Dependency, recuperation and the treatment through ayahuasca: definitions and indefinitions
Mercante, M. S. (2013) · Saúde & Transformação Social / Health & Social Change
Turn on and tune in to evidence-based psychedelic research
Conceptualizing, C. X., & Ma, K. (2015)
UNIVERSIDADE FEDERAL DE PERNAMBUCO CENTRO DE FILOSOFIA E CIÊNCIAS HUMANAS DEPARTAMENTO DE PSICOLOGIA DOUTORADO EM PSICOLOGIA COGNITIVA
Escobar, J. A. C. (2012)
Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder?
Sessa, B. (2017) · Journal of Psychedelic Studies · doi:10.1556/2054.01.2016.003
Geschichte der Psychedelika in der Medizin
Sessa, B. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_99
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Eischens, P., & Atherton, W. L. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.005 · Cited by 3
Innovative pharmakologische Ansätze zur Behandlung von Suchterkrankungen
Majić, T., Gutwinski, S., Müller, C. A., Schoofs, N., & Heinz, A. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00006-0
Transformative Psychopharmacology: the Case of 5-Methoxy-N,N-Dimethyltryptamine
Hesselink, J. M. K., & Hesselink, J. M. K. (2019) · International Journal of Psychotherapy Practice and Research · doi:10.14302/issn.2574-612x.ijpr-18-2503
NEW DEVELOPMENTS IN THE TREATMENT OF ALCOHOL USE DISORDER
Bonea, M. (2019) · FARMACIA · doi:10.31925/farmacia.2019.2.3
Il Default Mode Network: la scoperta, la struttura, le proposte teoriche
Mancuso, L. (2019) · RICERCHE DI PSICOLOGIA · doi:10.3280/rip2019-002001
Cognitive research on addiction in a changing policy landscape
Dawson, A., Hall, W., & Carter, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815298-0.00024-1
Hur upplevda livsförändringar relaterar till enskilda, handledda psykedeliska sessioner
Ekeberg, D. (2014) · DiVA (Södertörn University)
Efeitos agudos e subagudos de dose única de Ayahuasca no reconhecimento de expressões faciais
Rocha, J. M. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2020.tde-13042020-155227
Club Drugs and Novel Psychoactive Substances
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106
A Brief History of NPS Production and Distribution
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.003
Stimulant Drugs: Synthetic Cathinones
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.011
Stimulant Drugs: Methamphetamine
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.009
Classification Framework for Club Drugs and NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.004
Stimulant Drugs: Amphetamine-Type Stimulants
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.008
Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.013
The Clinical Challenge of Club Drugs and NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.005
Depressant Drugs: Benzodiazepine NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.015
Stimulant Drugs: Cocaine
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.007
Synthetic Cannabinoid Receptor Agonists (SCRAs)
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.017
Stimulant Drugs: MDMA and Drugs with Similar Effects
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.010
What Are Club Drugs and NPS and Why Are They Important?
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.002
An Evaluation of Diverse Therapeutic Interventions for Substance Use Disorders: Serotonergic Hallucinogens, Immunotherapy, and Transcranial Magnetic Stimulation
Meil, W. M., Farrell, W., & Satti, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98514
ルポ昼休みを生かしてリフレッシュ--東京急行電鉄(株)車両部長津田検車区 (作業の合間でリフレッシュ--休憩時間の過ごし方のヒント )
労働衛生編集部 (1995) · 労働衛生
The use of psychoactive substances in the treatment of mental disorders
Karaś-Ruszczyk, K., Groblińska, K., Szczygieł, K., & Samochowiec, J. (2021) · Alcoholism and Drug Addiction · doi:10.5114/ain.2021.111791
Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.014
Concluding Remarks
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.019
Depressant Drugs: Introduction
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.012
Psychedelika
von Heyden, M., & Jungaberle, H. (2017) · Springer eBooks · doi:10.1007/978-3-642-55214-4_43-1
Depressant Drugs: Ketamine and Its Analogues
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.016
Geschichte der Psychedelika in der Medizin
Sessa, B. (2017) · Springer eBooks · doi:10.1007/978-3-642-55214-4_99-1
Introduction
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.001
Hallucinogens
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.018
The Therapeutic Efficacy of Psilocybin in a Preclinical Model of Depressive- and Anxiety-Like Symptomology
Chafee, H. (2022) · doi:10.26686/wgtn.19579795
Pharmacological Action of LSD
Herian, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_131-1
Index
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.020
Hallucinogens
Nichols, D. E. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_44
Hallucinogens
Nichols, D. E. (2013) · Springer eBooks · doi:10.1007/978-3-642-27772-6_44-2

Authors: Krebs, T. S., & Johansen, P.-Ø.
Affiliations: Harvard University (US)
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2012-03-08
Volume: 26
Issue: 7
Pages: 994-1002
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881112439253
OpenAlex: W1973613743
Cited by: 583
References: 39
Citations by year: 2026: 39 · 2025: 55 · 2024: 67 · 2023: 63 · 2022: 59 · 2021: 52 · 2020: 55 · 2019: 25 · 2018: 34 · 2017: 29 · 2016: 31 · 2015: 25 · 2014: 23 · 2013: 19 · 2012: 6
FWCI: 3.40
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: lysergic acid diethylamide, LSD, alcoholism, alcohol abuse, psychedelic therapy, alcoholism treatment, treatment efficacy
MeSH terms: Adult, Alcoholism, Combined Modality Therapy, Hallucinogens, Humans, Lysergic Acid Diethylamide, Randomized Controlled Trials as Topic, Substance Abuse Treatment Centers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks